What B2B Tech Investors Look For, From Seed to Series A

Escaping GenAI Pilot Purgatory With Measurable ROI

Published on : February 12, 2026

Products That Count recently featured Rakshana Balakrishnan (Oracle Database at AWS) on why so many promising AI initiatives stall: teams ship pilots without a defensible way to measure ROI, validate unit economics at scale, or decide what to stop.

Here’s what it means for founders, and what VCs look for from seed to Series A. VCs aren’t funding pilots. They’re funding repeatable ROI. (This is especially relevant for AI-native companies right now, where costs can scale faster than value if you don’t design for economics early.)

TL;DR

  • VCs do not fund pilots. They fund repeatable ROI that survives procurement and finance scrutiny.

  • “Time saved” is not an ROI story unless it ties to a budget line and a measured counterfactual.

  • Seed is about a fast learning loop with instrumentation and kill criteria, not broad rollouts.

  • Series A diligence zooms in on variable costs, inference at 10x usage, and margin control.

  • Governance is product strategy: quality bars, monitoring, and a real stop button.

  • The best GenAI roadmaps prioritize workflow flips that change decisions, not chat demos.

Why GenAI pilots fail even when the demo looks great

Most GenAI programs do not die because the model is bad. They die because nobody can prove the pilot moves the P&L, and nobody in the org wants to sponsor a rollout on vibes.

  • If finance cannot audit the outcome, you do not have ROI. You have anecdotes.

  • If the buyer cannot defend the numbers internally, the champion will lose.

  • If you cannot show a baseline and a counterfactual, you cannot claim impact.

  • “Adoption” is not impact. Usage can rise while economics get worse.

  • The fastest path to pilot purgatory is a pilot with no stop conditions.

  • When pilots expand before measurement, you create political cost with no proof.

An MIT-affiliated analysis reported that about 95% of enterprise GenAI pilots show no measurable impact on profit and loss, which explains why “pilot purgatory” is now the default state for many programs.

The investor question that kills most GenAI roadmaps

At seed, investors can underwrite learning. By Series A, they underwrite repeatability. GenAI exposes founders who treat economics as something to clean up later.

  • Seed tolerance: “Show me a credible plan to learn fast and narrow uncertainty.”

  • Series A bar: “Show me a machine that repeats ROI across customers.”

  • The failure mode is usually economic discipline arriving after the build.

  • Reverse-engineering a business case in front of a skeptical exec is a losing game.

  • If the workflow does not change, ROI rarely changes.

  • If the user can ignore the feature and keep working the old way, it will not scale.

Gartner’s public forecasts have made that investor skepticism sharper. Gartner predicted that more than 40% of agentic AI projects will be canceled by the end of 2027 due to costs, unclear business value, or inadequate risk controls, even while expecting meaningful adoption by 2028 in enterprise software.

What investors mean by measurable ROI in B2B GenAI

Founders often sell “time saved.” Buyers often nod. Investors often shrug. Time saved only becomes ROI when it converts into a tracked business lever with a clear owner.

  • Cost-down ROI that survives diligence: fewer tickets, fewer hours, fewer errors, fewer reworks.

  • Revenue-up ROI that survives diligence: higher conversion, faster sales cycles, better retention, higher expansion.

  • “Productivity” counts when it changes staffing plans through attrition, not promises.

  • Tie the KPI to an existing dashboard the buyer already trusts.

  • Define the unit of value: per ticket, per claim, per invoice, per onboarded vendor.

  • Show time to break even using the customer’s own cost structure.

  • Prove the counterfactual: what happens in the same workflow without your product.

  • Build measurement into the product, not into a spreadsheet after the pilot.

This is why investors increasingly treat GenAI claims as noise until they see the measurement system. In practice, you are selling two products: the workflow capability and the instrumentation that proves it pays.

The PACE discipline that turns a pilot into a fundable roadmap

Balakrishnan’s PACE framing is useful because it forces prioritization before the build. The letters matter less than the operating discipline: pick measurable problems, segment the audience, make build-versus-buy decisions that do not crush margin, then model break even with real inputs.

  • Maintain a single backlog of candidate use cases with a single metric per use case.

  • Only greenlight use cases that map to a customer-owned budget and a tracked KPI.

  • Segment early: internal users tolerate iteration; external users demand reliability and security.

  • Decide “build vs buy” by total cost of ownership, not engineering preference.

  • Model unit economics at the feature level, not just at the company level.

  • Require an eval plan before code: quality thresholds, error tax, and escalation paths.

  • Set kill criteria upfront: thresholds that trigger pause, rollback, or a redesign.

  • Favor workflow displacement over “assistant” add-ons that do not change decisions.

When founders do this well, the roadmap becomes less shiny and more valuable. You stop chasing generic copilots and start shipping automation that changes cycle time, cost to serve, and error rates.

Seed-stage signals VCs want before they believe your ROI story

At seed, nobody expects perfect economics. Investors do expect proof that you can learn quickly, instrument end-to-end, and converge on a repeatable motion.

  • Start with one narrow workflow and define success in one sentence.

  • Instrument the workflow from input to outcome, including human review steps.

  • Show baseline performance before the model touches anything.

  • Run an honest counterfactual, even if it makes the early numbers smaller.

  • Explain failure modes and what you changed because of them.

  • Show movement in a metric that maps to dollars, not only engagement.

  • Be explicit about the buyer persona and where budget comes from.

  • Share kill criteria in the pitch. It signals discipline, not lack of conviction.

A common seed red flag is “pilot with no governor.” If the only plan is to keep expanding pilots until something works, you are not building a company. You are buying time.

Series A diligence: unit economics at scale and controlling variable AI costs

By Series A, the diligence lens shifts hard toward unit economics. Classic SaaS taught investors to assume low marginal costs. GenAI often introduces meaningful variable cost. If you cannot explain how margin behaves at 10x usage, you are exposed.

  • Know your COGS drivers: inference, retrieval, orchestration, labeling, human-in-the-loop.

  • Show cost per outcome, not just cost per token. Tokens are not value.

  • Model worst-case usage: long contexts, retries, heavy agent loops, peak-time spikes.

  • Have clear levers: model selection, caching, routing, context trimming, eval gates.

  • Prevent “customization creep” that turns the business into services.

  • Prove you can ship within enterprise constraints: security, audit, data residency, uptime.

  • Demonstrate that reliability improves over time through evals and monitoring, not heroics.

Gartner’s cancellation forecast is not only a market headline. It has become a diligence checklist item. Investors want to know how you avoid becoming one of the projects that gets cut when budgets tighten and the CFO asks for proof.

Governance is product strategy, not bureaucracy

One of the sharpest investor questions is simple: who can stop this? If nobody has authority to pause a GenAI feature that looks successful on the surface, you are taking enterprise risk without enterprise controls.

  • Define a quality bar that matters: accuracy, latency, safe completion, policy compliance.

  • Monitor drift and degradation over time, not only at launch.

  • Maintain a control dashboard that product, security, and support all use.

  • Build a real rollback path and a kill switch that has been tested.

  • Decide escalation rules for edge cases and high-stakes actions.

  • Treat trust as a measurable product requirement, not a marketing claim.

  • Make governance cross-functional so decisions are not trapped in one team.

The outcome investors want is not perfection. It is control. Control is what turns GenAI from a demo into an enterprise vendor posture.

Watch/read the Products That Count session: Cracking the GenAI ROI Paradox: Turning Pilots into Profit-Driving Products (Rakshana Balakrishnan).